KneeStimTM

Wearable, Personalized, Dynamic Medical Devices for Mobile Rehabilitation

South by Southwest 2014

Knee Joint Rehabilitation Market

Pre-Surgical Dysfunction• 30M patients (9.5% US population)

w/ evidence of knee osteoarthritis

• 11M patients symptomatic, seeking treatment

• Incidence increasing with age & obesity

1994

Post-Surgical Rehabilitation • US, 2011: 730,000 replacements,

55,000 revisions

• $9B annual cost

• Procedure volume growing @ 8%/yr.

• 2M replacements/yr. by 2020

Limitations of Existing Treatments

$5B Pre-Surgical Market

Current Treatments Drawbacks/Adverse Events

OTC remedies (Chondroitin) Headache, diarrhea, vomiting, swelling of knee

OTC Acetaminophen Liver toxicity & limited pain relief

NSAIDs Stomach discomfort, gastrointestinal bleeding

Narcotics Addiction, constipation, drug-drug interactions

Hyaluronic Acid Injections Risk of infection and limited duration

Steroid Injections Atrophy and limited term of benefit

Unloader Knee Brace Doesn’t address atrophy, cumbersome, compliance

KneeStim™Mobile Rehabilitation Solution

Stimulates quadriceps muscles during everyday movements

Features• Differential muscle stimulation

based on joint state• Real-time reaction to movement• Kinematic data collection• Light, form-fitting, comfortable

Potential Benefits

• Re-strengthened and re-educated quadriceps

• Accelerated rehabilitation• Reduced rehabilitation costs • Improved functional outcomes

Unmet Needs in Rehab Market

Orthopedic Surgeons

● Use data to document treatment necessity

● Help patients on waiting list

Hospitals & Clinics

● Preserve margin on treatment

● Improve procedure outcomes

● Monitor patients, gain data with fewer office visits

Physical Therapists

● Spend time on issues more complex than building strength

● Get feedback over time on patient's physical improvement

All

Improve rehabilitation

Accumulate data on progress

Save time and money

Proven Team

Corporate Office3 Concord AveSuite #43Cambridge, MA 01238P: (617) 714-5125

Research LabsAustin, TX 78704P: (512) 366-3063info@articualtelabs.com

www.articulatelabs.com

Rick Pierce, Chief Executive Officer Javelin Pharmaceuticals (NYSE amex: JAV) sold to Hospira

(01/07/10), GlycoGenesys (NASDAQ: GLGS), SafeScience (NASDAQ: SAFS), Lehman Brothers, Merrill Lynch

Herbie Kirn, Chief Science Office & Co-FounderFounder, Jam Technologies; Senior Systems Engineer for GM and Chrysler advanced research facilities

Josh Rabinowitz, Chief Operating Officer & Co-FounderGrant writing, research, policy analysis, communications

Gavan Goss, Chief Financial Officer CFO, Dell Financial Services and Citigroup Finance; M&A

Barbara Rohan, Gov’t Affairs, Public Policy & Reimbursement*VP, Gov’t Affairs, Public Policy & Reimbursement - Smith & Nephew

Janie Gentry Bates, Senior Marketing Strategist*VP Marketing - Smith & Nephew

Mary Kelly, Senior Reimbursement Specialist*Pfizer, Amgen, Smith & Nephew, Genzyme Bio-Surgery

Marco Valez-Duran, Clinical, Regulatory & Quality*VP, Clinical, Regulatory, and Quality – Smith & Nephew

* = Contractor/Consultant

Thank you

Josh Rabinowitz, Co-Founder & COOjrabinowitz@articulatelabs.com

O: (512) 366-3063M: (248) 408-1503